Hematopoietic growth factors are being administered to patients with acute myeloid leukemia (AML) both to shotten the duration of chemotherapy-induced neutropenia and in an attempt to increase cytotoxicity of cell cyclespecific agents. However, limited information is available concerning the effects of growth factors in AML patients. To examine the in vivo effects of recombinant human granulocyte colony-stimulating factor (G-CSF) on AML cells, laboratory studies were performed before and after a 72-hour intravenous infusion of G-CSF (10 pg/kg/d) administered to 28 untreated AML patients. Twenty-seven patients (96%) showed increases in at least one of the following parameters after G-CSF blood blasts, bone marrow (BM) blasts, leukemia cells in S phase or interphase cells with leukemia-specific markers shown by fluorescence in situ hybridbation. The median paired change in absolute blast count was +2.7 x EMATOPOIETIC GROWTH factors with the capacity to stimulate myeloid progenitor cells are being administered to patients with acute myeloid leukemia (AML) both to shorten the period of chemotherapy-induced neutropenia and in an attempt to increase sensitivity to killing by cell cycle-active drugs.' Hematopoietic growth factors are also in widespread use in conjunction with potentially leukemogenic cytotoxic therapy for nonhematologic malignancies, with the goal of shortening neutropenia. Growth factors are known to promote growth of AML cells in vitro, but relatively little is known about their in vivo effects in AML patients.
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We administered recombinant human granulocyte colonystimulating factor (G-CSF) to 28 patients with untreated AML before initiation of induction chemotherapy. We performed laboratory studies before and after administration of G-CSF to examine in vivo effects of G-CSF on leukemia cells. CD13 , and HLA-DR coexpre~sion.~ Percentages of leukemia cells in G&, and in Gz/M phases were also determined. Data were acquired on the FACStar Plus flow cytometer (Becton Dickinson, San Jose, CA) and were analyzed using the WinList multiparameter analysis software (Verity Software House, Inc, Topsham, ME) and the Modfit program for cell cycle analysis (Verity Software House).
Cytogenetics. Pre-G-CSF samples were karyotyped in all cases. BM was studied in 27 patients, and blood in 1 patient. Cytogenetic analyses were repeated after G-CSF in 10 patients using the same sample source (BM in 9 patients, blood in 1) and identical preparative techniques. Samples were processed using short-term unstimulated cultures (24-72 hours). A minimum of 20 G-banded metaphase cells were analyzed in each case. Clonality criteria and descriptions of chromosome aberrations were according to the International System for Human Cytogenetic Nomenclature (1991).* Clonal abnormalities were identified in pretreatment samples from 20 patients (71%).
Mitotic index. The mitotic index, defined as the percentage of cells in mitosis among 2,000 cells counted, was determined in patients' pre-and post-G-CSF samples processed identically for cytogenetic analysis.
Fluorescence in situ hybridization (FISH) FISH was performed on BM and blood smear slides from 6 patients with monosomy 7 or trisomy 8 using directly labeled cy-satellite DNA probes specific for the centromeric regions of chromosomes 7 or 8 (SpectrumGreen CEP-7 and CEP-8; Vysis, Naperville, L). Slides were visualized on a Zeiss (New York, NY) Axioscope microscope. Hybridization signals were counted in 1,000 BM cells or 100 blood or BM neutrophils.
Multidrug resistance studies. P glycoprotein (P-170) was detected by flow cytometric analysis of reactivity with the MRK16 monoclonal antibody (provided by Dr T. Tsuruo, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan). Indirect labeling with phycoerythrin-conjugated goat antimouse F(ab'), (Caltag, San Francisco, CA) was used to detect MRK16 binding. Flow cytometry was performed on the FACScan (Becton Dickinson). Analysis was performed using WinList software.
Staristical methods. The Wilcoxon signed-rank two-tailed test was used to test the location of the distribution of paired differences between laboratory parameters measured before and after G-CSF, as well as 72 hours before and immediately before initiation of G-CSF. A significance level of .05 was used. Additionally, relative changes in laboratory values for samples studied before and after G-CSF were computed. Mitotic index before and after G-CSF was compared in each patient using the Fisher's exact two-tailed test. Increase in the percentage of BM cells with monosomy 7 or trisomy 8 by FISH after G-CSF was tested with the sign test (one-tailed).
RESULTS
Twenty-seven patients (96%) showed increases in at least one of the following parameters after G-CSF: blood blasts, BM blasts, BM leukemia cells in S phase, or interphase cells with leukemia-specific markers determined by FISH (Table  1) . G-CSF responses were observed in all FAB types. It is of note that, although G-CSF is a granulocytic growth factor, ABCs also increased markedly in patients with monocytic leukemia (FAB M5). White blood cell counts (WBCs), ABCs, and percentage of leukemia cells in S phase all decreased in a single patient (patient no. 3; see Table l) .
WBCs were higher after G-CSF in 26 of 28 patients, with 2100% increases in 22 ( Fig 1A and Table 1 ). Blood ABCs increased in 22 patients ( 2 100% increase in 12), remained unchanged in 5, and decreased in 1 patient (Fig 1B and Table   1 ). Absolute neutrophil counts (ANCs) increased by 2 100% in 22 patients, increased by 210% in another 3 patients, showed a less than 10% change in 2, and decreased by 2 10% in 1 patient (Fig 1C and Table l) . There was also an increase in the numbers of intermediate forms (myelocytes and metamyelocytes) in most patients' blood after G-CSF (data not shown). Differences between distributions of WBC, ABC, and ANC before and after G-CSF were all highly significant (Table 2) .
To evaluate whether the increases in WBC, ABC, and ANC after G-CSF were likely to have been caused by G-CSF, we examined the changes in blood counts during the 72-hour period before initiation of G-CSF in 25 patients for whom these data were available (Figs lA, B, and C). Median paired differences in WBC, ABC, and ANC 72 hours before G-CSF was started and immediately before initiation of G-CSF were -0.5 X lo9&, 0.0, and -0.6 X lo9& respectively, and distributions of these parameters were not different at the two time points (P = .12, 31, and .62, respectively).
Thus, counts remained relatively stable during the 72 hours before initiation of G-CSF and then increased significantly after G-CSF was initiated. This suggests that the increases in blood counts that occurred in most patients during administration of G-CSF were in fact caused by G-CSF. Although it is possible that increases in blood counts during G-CSF reflect changes in the BM that occurred several days earlier, ie, before the initiation of G-CSF, there is no reason to assume anything other than a steady state before initiation of G-CSF.
Platelet counts decreased during G-CSF administration in 10 of 13 patients who did not receive platelet transfusions (Fig 1D) . The distribution of platelet counts was significantly different in untransfused patients before and after G-CSF (Table 2 ). Platelet counts also decreased significantly ( P = .02) during the 72 hours before initiation of G-CSF in these patients (Fig lD) , with a median paired difference of -18 X 109/L. Thus, the overall decrease in platelet count during G-CSF continued an ongoing trend. However, patterns of change in platelet counts were heterogeneous. The rate of decrease in platelet count was unchanged before versus during G-CSF in 4 patients. An accelerated decrease in platelet count was observed in 6 patients, whereas 2 patients' platelet counts actually increased during G-CSF.
Serum lactate dehyrogenase (LDH) values (Fig 1E) increased significantly during administration of G-CSF ( Table  2 ). The median paired change in LDH values during the 72-hour period before initiation of G-CSF was a decrease of 26.5 IUL ( P = .M) for 20 patients for whom these values were available. Thus, it was likely that the increases in serum LDH values that occurred during G-CSF were caused by G-CSF. Other serum chemistry values, including aspartate aminotransferase, bilirubin, and alkaline phosphatase levels, did not change during G-CSF (data not shown).
Percentages of myeloblasts in the BM increased in 11 of the 23 patients studied after G-CSF, remained unchanged in 7, and decreased in 5 ( Table 1 and Fig 2A) . The greatest increases in BM myeloblasts were observed in the 2 patients with FAB M6 AML, from 16% to 56% and from 25% to 59%. Despite the striking changes in some patients, the per- centage of BM blasts considered among all patients was not significantly different before and after G-CSF ( Table 3) . Using multiparameter flow cytometry to gate on leukemia cells in the BM before and after G-CSF, we showed increased percentages of leukemia cells in S phase after administration of G-CSF in 12 of 15 patients ( Table 1 and Fig  2B) . The median percentage of BM leukemia cells in S phase increased almost twofold, from 6.0 to 10.7 ( Table 3) . The difference in distribution of leukemia cells in S phase before and after G-CSF was highly significant ( Table 3) . Increases in BM leukemia cells in S phase did not correlate with increases in BM blasts ( Table 1) . There was better correlation between increases in BM leukemia cells in S phase and increases in blood ABC ( Table 1) . Although S phase cells increased significantly after G-CSF, percentages of leukemia cells in S, G2, and M phases combined were still low after G-CSF, ranging between 0.8% and 24.1% (median, 15.3%). Thus, the majority of leukemia cells had not entered or gone through S phase at completion of G-CSF.
Results of cytogenetic analyses performed before and after G-CSF in 10 patients are presented in Table 4 . Three patients with clonal chromosomal aberrations in all cells before G-CSF (category A A , patients no. 13, 15, and 16) also had exclusively abnormal metaphases after G-CSF.
In 4 of 5 cases with both normal and abnormal metaphases (category A N ) before G-CSF (patients no. 5, 20, 21, and 28), higher percentages of abnormal metaphases were observed after G-CSF, but the differences were not significant. In 2 patients with complex karyotypes and one or more sidelines in pre-G-CSF samples (patients no. 16 and 28), additional sidelines were apparent after G-CSF. The B M mitotic index increased significantly after G-CSF in 2 of 6 patients (patients no. 13 and 15). Changes in mitotic index and in the percentage of leukemia cells in S phase correlated in 3 of 4 patients in whom both were determined (both increased in patients no. 13 and 28 and both decreased in patient no. 24). In patient no. 16, the mitotic index decreased, but two new sidelines were evident after G-CSF. Interestingly, the percentage of leukemia cells in S phase increased in this patient after G-CSF.
FISH analysis of interphase cells with chromosome-specific probes was used to study the effect of G-CSF on the percentages of BM cells with monosomy 7 (patients no. 5, 13, and 17) or trisomy 8 (patients no. 14, 21, and 27). BM cells with monosomy 7 or trisomy 8 increased in all 6 patients after G-CSF, with relative increases of 27% to 105% (median relative increase, 47%; see Table 5 ). If normal and abnormal cells responded similarly to G-CSF, there would be an equal chance that the percentage of cells with clonal chromosomal abnormalities would increase or decrease after treatment with G-CSF, and the probability that this percentage would increase in all 6 cases by chance alone is .02. Therefore, it is suggested that cells with leukemia-specific chromosomal abnormalities increased during G-CSF to a significantly greater extent than those without.
We determined the percentages of cells with the multidrug-resistance phenotype in pre-and post-G-CSF BM samples using flow cytometric analysis of reactivity with the MRK16 antibody. There was little change in the percentage of BM cells staining with MRK16 in any of the 15 patients studied before and after G-CSF (Fig 2C and Table 3) .
Because blood neutrophil counts increased significantly after in vivo administration of G-CSF, we sought to determine whether G-CSF enhanced differentiation of leukemic clones. To this end, we used FISH with chromosome-specific probes to study neutrophils in patients with monosomy 7 and trisomy 8 before and after G-CSF (Table 6 and Fig 3) .
Percentages of BM neutrophils with monosomy or trisomy did not change significantly in any patient before and after G-CSF. BM neutrophil populations were predominantly or partially abnormal by FISH in 4 patients and were largely normal in 1. Blood neutrophils present after G-CSF derived completely or partially from cytogenetically abnormal clones in 4 of 6 patients, but these patients also had cytogenetically abnormal BM neutrophils before G-CSF. Thus, although blood neutrophil counts were higher after G-CSF, G-CSF did not appear to increase granulocytic differentiation of leukemic clones relative to that in normal cells in AML patients. Treatment outcomes are shown in Table 1 , including achievement of CR after remission induction therapy and CR duration. There were 6 induction deaths, none of which were related to G-CSF therapy. Of 22 patients who survived remission induction therapy, 18 achieved CR. The 4 patients who did not achieve CR all had hypocellular BMs without abnormal myeloblasts after completion of chemotherapy, but leukemia became apparent in subsequent BMs (days 43, 66, 74, and 75). It is of note that the 4 patients with induction failure caused by regrowth of leukemia included the only patient with no apparent response to G-CSF (patient no. 3), as well as the only other patient whose WBC did not increase during G-CSF (patient no. 26). Remission durations have varied considerably among patients whose cells were highly responsive to G-CSF and included both short (eg, patients no. 21 and 27) and long (eg, patient no. 22) disease-free intervals. Of note, 4 of 4 patients with 2100% increases in BM leukemia cells in S phase who achieved CR had CR durations of 5 8 months. However, the significance of this observation is unclear because the numbers of patients are too small for statistical comparisons of remission durations.
DISCUSSION
A total of 27 of 28 patients (96%) treated with G-CSF before remission induction chemotherapy showed increases in at least one of the following parameters after G-CSF: blood blasts, BM blasts, leukemia cells in S phase, or interphase cells with leukemia-specific markers as shown by FISH. Increases in blood blast counts and in the percentage of leukemia cells in S phase after G-CSF were highly significant. Moreover, BM populations with leukemia-specific markers increased after G-CSF in all patients studied, which is consistent with expansion of leukemic populations after short term G-CSF therapy. Blood neutrophil counts also increased in 26 of 28 patients after G-CSF, and the overall increase in blood neutrophil counts was highly significant. In contrast, despite large increases in the percentage of BM blasts in some patients, the percentage of BM blasts considered among all patients was not significantly different before and after G-CSF. Lack of significant increase in the percentage of BM blasts was likely caused by the expansion of both blasts and granulocytes in the BM after G-CSF. Our findings have implications for the biology of AML as well as for the use of growth factors as part of AML therapy.
We have shown responsiveness of AML cells to shortterm in vivo administration of G-CSF in almost all patients. G-CSF receptors have been found to be present on the surface of leukemia cells in most cases of AML, but in vitro responsiveness to G-CSF is not observed in all cases in which receptors are pre~ent.~"' G-CSF receptors were shown in 70 of 72 cases of AML (97%) in four series, but in vitro For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Clinical trials of growth factor priming in AML reported to date have generally not shown clinical benefit."." Estey et a124 reported a lower CR rate and a higher incidence of resistant disease in previously untreated patients receiving granulocyte-macrophage CSF (GM-CSF) for up to 8 days before chemotherapy, as compared with those of historical control patients matched for prognostic factors. Ohno et a125 found that 2-day administration of G-CSF before chemotherapy for refractory AML had no effect on CR rate or duration. Similarly, Estey et a126 found that administration of G-CSF to previously untreated patients for 1 day before chemotherapy had no effect on CR rate. The sole positive clinical trial to date was reported in abstract form by BIichner et al,27 who found similar CR rates but longer CR durations in previously untreated patients receiving GM-CSF for 24 hours before both induction and consolidation therapy. The patients whose studies are reported here represent a subset of patients treated on the priming arm of a randomized clinical trial of G-CSF priming. Analysis of treatment results shows no difference in treatment outcome on the priming and nonprim- Patient numbers are the same as in Table 1 .
Abbreviations: AA, exclusively abnormal; AN, abnormal and normal; NN, exclusively normal metaphases; ND, not determined; cx, complex karyotype; SI, stemline; sdl, sideline. * P < .05. t Additional cell(s) with nonclonal abnormalities Dresent.
For Patient numbers are the same as in Table 1 .
* Pre-and post-G-CSF.
t P = .oz.
* (Post-G-CSF -pre-G-CSF value/pre-G-CSF value) x 100.
ing arms of the study. Thus, although priming strategies (choice of growth factor, dose, route, and duration) have differed, as have chemotherapy regimens, the clinical experience with growth factor priming to date has been largely negative.
Biological effects of growth factors have not been extensively studied in conjunction with most clinical trials. In three GM-CSF priming studies,'"'" the percentage of Sphase cells increased in 17 of 20 patients who received 18-to 72-hour GM-CSF infusions before chemotherapy. These data are similar to our findings with G-CSF priming. In the study reported by Ohno et al," the percentage of BM blasts did not change after 2 days of G-CSF priming. We have shown here that the percentage of BM blasts is not a sensitive indicator of growth factor responsiveness. Therefore, it is possible that AML cells in S phase increased after G-CSF priming in the study by Ohno et a1 despite the lack of increase in the percentage of BM blasts. Biological effects of priming were not studied in other clinical trials reported to date. '4,'6,'7 The results presented here show that the priming regimen that we used was effective in increasing the percentages of AML cells in S phase in most patients. There was no direct correlation between the magnitude of the biological effects BAER ET AL of G-CSF and treatment outcome in each patient. Observations in small numbers of patients suggested possible associations between G-CSF unresponsiveness and remission induction failure and between marked increases in S-phase cells after G-CSF and brief CR durations; however, the numbers of patients were too small to assess the significance of these observations.
Based on analysis of the effects of in vivo administration of G-CSF before chemotherapy reported here, there are several reasons for which priming might not favorably affect treatment outcome. First, although G-CSF was effective in increasing percentages of leukemia cells in S phase, the majority of AML.
cells did not enter S phase during administration of G-CSF, as has also been seen in other priming trials.28-30 Therefore, it is possible that the effects of G-CSF on the percentage of leukemia cells in S phase, although statistically sigmficant, are not of sufficient magnitude to effect a clinically significant change in chemosensitivity. Secondly, expansion of the mass of leukemia cells during administration of G-CSF was strongly suggested based on the results of FISH analyses. An increase in tumor burden may have a negative impact on treatment response that balances or outweighs the positive effects of increased cell cycling. Moreover, G-CSF might promote growth of resistant leukemic populations. There was no effect on populations with multidrug-resistance mediated by pglycoptein, but expansion of cells with drug resistance mediated by other mechanisms might have occurred.
An additional factor with potential relevance to impact on clinical outcome is the mechanism by which the increase in BM leukemia cells in S phase occurred during G-CSF therapy. Because DNA flow cytometry does not allow cells in Go and G, to be distinguished, it is unclear whether the increases in the percentage of cells in S phase after G-CSF were caused by recruitment into active cycle of cells that would otherwise have remained in Go. by accelerated cycling of cells that were already in G, before G-CSF and were, therefore, already committed to complete the cell cycle, or by a combination of the two. Even if increases in S-phase cells were caused only by accelerated cycling, chemosensitivity should have increased due to the greater likelihood that leukemia cells would enter S phase during the time period in which chemotherapy was administered, because long cell cycle times are seen not infrequently in AML." However, if leukemia cells that would otherwise have remained in Go were recruited into active cycle by G-CSF, the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From effect of priming on chemosensitivity might be of greater magnitude than that expected with accelerated cycling alone.
We also explored the possibility that G-CSF might induce differentiation of AML cells. Significant increases in blood neutrophil counts were observed after in vivo administration of G-CSF. AML is characterized by maturation arrest of the malignant clone, with accumulation of malignant myeloblasts in the BM and impaired granulopoiesis. Nevertheless, mature neutrophils have been shown to derive from leukemic clone^.^**^^ Moreover, G-CSF has been shown to enhance neutrophilic differentiation of AML cells in vitro." Using FISH, we showed monosomy 7 or trisomy 8 in BM andor blood neutrophils in 5 of 6 patients with these cytogenetic abnormalities, but percentages of neutrophils with monosomy or trisomy were not significantly different in any patient before and after G-CSF. Thus, although blood neutrophil counts were higher after G-CSF, G-CSF did not appear to selectively promote granulocytic differentiation of leukemic or normal cells in AML patients.
Of additional concern is the potential impact of priming before induction therapy on CR duration. If priming enhanced the chemosensitivity of residual leukemia cells present in CR, it could have a favorable impact on CR duration. Alternatively, however, presence of an expanded population of chemoresistant cells in the BM at attainment of CR could adversely affect CR duration. Because widely applicable techniques for studying residual disease in AML are not yet available, the effects of priming on residual disease in CR BM are not readily able to be studied at this time.
We have shown that leukemia cells are highly responsive to G-CSF in vivo in the vast majority of cases of AML. Although our data might raise concern about the use of G-CSF after chemotherapy to attenuate hematologic toxicity in patients with AML, clinical trials to date in which growth factors are administered to AML patients after effective leukemic cytoreduction with the goal of accelerating recovery of normal hematopoiesis have not shown a higher incidence of resistant disease or leukemic regrowth or a higher relapse rate. 35"7 Our demonstration that leukemia cells are highly responsive to G-CSF in vivo also adds a cautionary note with respect to administration of G-CSF to patients with malignancies other than AML in conjunction with therapy that may induce AML. There is, as yet, limited knowledge about the impact of hematopoietic growth factor therapy on the development of treatment-related leukemias. The data reported here would suggest that growth factors could promote proliferation of abnormal clones once leukemogenic events had ocurred. The incidence and time to onset of treatmentrelated leukemias must be closely scrutinized in patients receiving hematopoietic growth factors with therapy that has been associated with subsequent development of leukemia. recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4826, 1990 17. Santini V, Nooter K, Delwel R, Lowenberg B: Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): Asessment in vitro after stimulation with colony stimulating factors (CSFs). Leuk Res 14377, 1990
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